BrightSpring Health Services, Inc. Stock Price, News & Analysis

BrightSpring Health Services (NASDAQ: BTSG) has scheduled the release of its first quarter 2025 financial results for Friday, May 2, 2025. The announcement will be made before the company's earnings conference call, which is set for 8:30 a.m. ET on the same day.

Interested participants can register for the conference call prior to the 8:30 a.m. ET start time. The company will make both a live and archived webcast available on their investor relations website at ir.brightspringhealth.com under the 'Events & Presentations' section, where related presentation materials will also be posted before the call.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q4 and full year 2024 results, with significant revenue growth and improved profitability. Q4 net revenue increased 28.6% to $3,053 million, with net income of $15.4 million compared to a loss in Q4 2023. Full year revenue grew 27.6% to $11,266 million, while net loss improved to $20.5 million from $156.8 million in 2023.

The company announced plans to divest its Community Living business to Sevita for $835 million. For 2025, BrightSpring increased guidance (excluding Community Living), projecting revenue of $11,600-$12,100 million (15.2-20.1% growth) and Adjusted EBITDA of $545-560 million (18.4-21.7% growth). The Pharmacy Segment is expected to grow 15.9-21.1%, while the Provider Segment is forecast to grow 10.0-13.8%.

BrightSpring Health Services (NASDAQ: BTSG) has announced the promotion of Jennifer Phipps to Chief Financial Officer, effective March 4, 2025, succeeding Jim Mattingly. Phipps, who brings over 20 years of healthcare financial experience, has served at BrightSpring for eight years in multiple roles including Chief Accounting Officer and CFO of the Home Health and Hospice segment.

During her tenure at BrightSpring, Phipps has led technology implementations to streamline financial processes, built a lean-focused procurement team, and implemented various accounting systems. She played a important role in the company's IPO and has maintained active involvement in public company processes. Prior to BrightSpring, she held leadership positions at Cardinal Health and spent six years at Ernst & Young.

Phipps holds a CPA license and received her Bachelor's and Master's in Accounting from The Ohio State University. She will lead BrightSpring's financial operations, supporting the company's mission of providing community-based pharmacy and provider health solutions to complex populations.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, before market open. The company will host an earnings conference call at 8:30 a.m. ET on the same day.

Interested participants can register for the conference call online. A live and archived webcast of the call will be available on the company's investor relations website, along with related presentation materials which will be posted prior to the call.

BrightSpring Health Services (NASDAQ: BTSG) has announced the sale of its Community Living business to Sevita for $835 million in cash. The transaction, expected to close in 2025, will generate approximately $715 million in after-tax proceeds, primarily used for debt reduction.

The divested Community Living business is projected to generate about $1.2 billion in Revenue and $128 million in Adjusted EBITDA for 2024. Post-divestiture, BrightSpring will focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Primary Care.

The company reported preliminary 2024 results above previous guidance, with expected Net Revenue of $11.2-11.3 billion and Adjusted EBITDA of approximately $588 million. For 2025, excluding Community Living, BrightSpring projects Net Revenue of $11.5-12.0 billion and Adjusted EBITDA of $540-555 million.

BrightSpring Health Services (NASDAQ: BTSG) has successfully refinanced its entire $2.55 billion Term Loan B facility due February 2031 through its subsidiary Phoenix Guarantor Inc. The refinancing resulted in a reduced interest rate, with the facility now priced at SOFR +250 basis points, down from SOFR +325 basis points. This 75 basis point reduction is expected to generate annual cash interest savings of approximately $19.1 million. The transaction was completed without incurring any additional debt, with Morgan Stanley and KKR Capital Markets acting as lead bookrunners.

BrightSpring Health Services (NASDAQ: BTSG) announces that its specialty pharmacy partner, Onco360®, has been selected as the national pharmacy partner for multiple new medications treating advanced cancers and blood diseases. Eight new medications have been added to Onco360's distribution network, including treatments for: breast cancer (ITOVEBI™), myelodysplastic syndromes (Rytelo™), brain tumors (Voranigo®), paroxysmal nocturnal hemoglobinuria (PIASKY®), esophageal cell carcinoma (Tevimbra®), non-small cell lung cancer (LAZCLUZE™), acute leukemias (Revuforj®), and gastric tumors (Vyloy®).

BrightSpring Health Services (NASDAQ: BTSG) has announced its participation in two upcoming virtual investor conferences. The company will take part in the BTIG Virtual Digital Health Forum Panel on November 25th at 9:00 AM ET and the Bank of America Virtual Home Care Conference 2024 Fireside Chat on December 10th at 2:10 PM ET. A live and archived webcast of the Bank of America conference session will be accessible through BrightSpring's investor relations website.

BrightSpring Health Services (NASDAQ: BTSG) announced that its subsidiary CareMed has been selected by Eisai as a national specialty pharmacy provider for Leqembi®, an innovative Alzheimer's disease treatment. The FDA-approved medication demonstrated effectiveness in slowing cognitive impairment progression over 18 months in Phase III clinical trials involving 1,795 patients aged 50-90 with early Alzheimer's disease. Leqembi is a monoclonal antibody targeting aggregated forms of amyloid beta, showing superior results compared to placebo in treating mild cognitive impairment and mild dementia stages.